Key result
Mitral valve repair in infective endocarditis was associated with better survival at 1 and 5 years and lower rates of recurrence and reoperation compared to replacement.
Why the study?
Does mitral valve repair improve survival and reduce morbidity compared to mitral valve replacement in patients with native valve infective endocarditis?
Meta-Analysis (n=8,978)
Does mitral valve repair improve survival and reduce morbidity compared to mitral valve replacement in patients with native valve infective endocarditis?
Mitral valve repair is associated with superior short- and long-term survival, fewer reoperations, and lower recurrence of endocarditis compared to valve replacement in patients with native valve infective endocarditis.
Answers are grounded in this paper and cite their sources.
Mitral repair was associated with lower mortality and recurrence in IE; leaves open preference over replacement pending randomized confirmation.
OBJECTIVE: The objective of this study is to review the morbidity and mortality associated with mitral valve repair versus replacement in infective endocarditis patients. METHODS: A comprehensive search was undertaken among the four major databases (PubMed, Embase, Scopus, and Ovid) to identify all available data comparing mitral valve repair or replacement in infective endocarditis. Databases were evaluated and assessed to March 2017. Data were analyzed using meta-analytical techniques including odds ratio and mean weighted difference. RESULTS: A total of 8978 patients were analyzed in a total of 14 articles. The average age of the cohort was 53 years. Results revealed a shorter CPB time in the mitral valve (MV) repair compared to replacement group (P = 0.05). Postoperative outcomes (30 days/in hospital events) such as bleeding (P = 0.0047) and recurrence of infective endocarditis (IE) (P = 0.004) were significantly lower in the MV repair group. Beyond 30 days, recurrence of IE was higher in the MV replacement than the repair group (P < 0.0001). Additionally, there were significantly less reoperations in the repair group (P = 0.0021). The MV repair group had significantly better survival at 1 and 5 years postop (P < 0.0001, P < 0.0001). CONCLUSION: This meta-analysis shows that mitral valve repair has good clinical outcomes both in-hospital and at 1 and 5 years of follow-up. Mitral valve repair should be attempted in those patients in whom sufficient valve tissue is present for reconstruction after all infectious tissue has been resected.
No takes yet. Share an insight, caveat, or question.
Harky et al. (2018) conducted a meta-analysis in Infective endocarditis (n=8,978). Mitral valve repair vs. Mitral valve replacement was evaluated on Survival at 1 and 5 years postoperatively (p=<0.0001). Mitral valve repair in infective endocarditis was associated with better survival at 1 and 5 years and lower rates of recurrence and reoperation compared to replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: